- GlobeNewswire•2 days ago
RESEARCH TRIANGLE PARK, N.C., April 24, 2017-- BioCryst Pharmaceuticals, Inc. today announced that its first quarter 2017 financial results will be reported on Thursday, May 4 th, 2017.. BioCryst will ...
- American City Business Journals•13 days ago
On the heels of announcing a $45 million secondary public offering of the company’s common stock last month, Durham-based BioCryst Pharmaceuticals (BCRX) plans to move forward with a new trial for its hereditary angioedema (HAE) therapy BCX7353. The company said it will explore a new oral liquid for treating acute attacks in patients with hereditary angioedema. It added that it has received “initial regulatory approvals in Europe” for the clinical trial.
- GlobeNewswire•14 days ago
RESEARCH TRIANGLE PARK, N.C., April 12, 2017-- BioCryst Pharmaceuticals, Inc., a pharmaceutical company focused on the development and commercialization of treatments for rare diseases, announced today ...
BCRX : Summary for BioCryst Pharmaceuticals, Inc. - Yahoo Finance
BioCryst Pharmaceuticals, Inc. (BCRX)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||6.21 x 100|
|Ask||6.75 x 800|
|Day's Range||6.32 - 6.56|
|52 Week Range||2.49 - 9.25|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-8.46|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|